Last reviewed · How we verify

NCT05623241

MONOCENTRIC PERSPECTIVE STUDY: USE OF LIQUID BIOPSY WITH DIAGNOSTIC IMAGING

Status unknown Last updated 21 November 2022
What this trial tests

trial testing Liquid Biopsy in Breast Cancer in 200 participants. Status unknown.

Timeline
12 September 2022
Primary endpoint
15 September 2023
22 September 2025

Quick facts

Lead sponsorUniversity of Campania Luigi Vanvitelli
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment200
Start date12 September 2022
Primary completion15 September 2023
Estimated completion22 September 2025
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

University of Campania Luigi Vanvitelli

Who can join

18 and older, female only, with Breast Cancer or Liquid Biopsy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluation of the diagnostic accuracy of Mammography in the morpho-structural analysis of mammographic images in breast cancer-diagnosed patients or patients in follow-up for breast cancer by extracting a number of features describing the texture and morphology of the lesions reported in the form of a structured report explicitly developed for the study. Correlation of the data obtained from evaluating the primary endpoint with the genetic/molecular analysis on liquid biopsy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Liquid Biopsy

Trials testing the same drug.

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

Other University of Campania Luigi Vanvitelli trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05623241.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing